Int J Cardiol. 2011 Aug 18;151(1):e10-1. doi: 10.1016/j.ijcard.2010.02.072. Epub 2010 Mar 19.
Recently, the feasibility and safety of percutaneous aortic valve replacement (PAVR) have been reported in the treatment of degenerative aortic valve stenosis in patients at high-risk for surgical aortic valve replacement (AVR). However, so far this therapy has been limited to patients with severe stenosis of the native valve. We report the case of an 84 year old patient with severe aortic regurgitation caused by infective endocarditis who was successfully treated by implantation of a CoreValve (CoreValve Inc, Irvine. Calif) prosthesis with a totally percutaneous approach.
最近,经导管主动脉瓣置换术(PAVR)在高危外科主动脉瓣置换术(AVR)患者退行性主动脉瓣狭窄的治疗中已被证实具有可行性和安全性。然而,到目前为止,这种治疗方法仅限于原生瓣膜严重狭窄的患者。我们报告了一例由感染性心内膜炎引起的严重主动脉瓣反流的 84 岁患者,该患者通过完全经皮途径成功植入 CoreValve(CoreValve Inc,加利福尼亚州欧文)假体。